Objectives: To quantify the number and costs of relapses avoided over 2 years in the first-line treatment of RRMS based on the findings of the Cochrane report. MethOds: An Excel-based financial model estimated the relapses and costs incurred by a hypothetical cohort of 1000 RRMS patients treated with first-line disease-modifying drugs (DMDs). The modelled cohort evaluated the consequences of treatment with subcutaneous (SC) interferon beta-1a versus intramuscular (IM) interferon beta-1a, as this was the only comparison whose data quality was assessed as 'high' by the Cochrane Review (Filippini et al., 2013). Risk of relapse was based on the 2-year data from the Cochrane Review network meta-analysis. The analysis was performed from a US payer perspective. The cost of a relapse was sourced from Panitch et al., 2005, and adjusted to 2012 US dollars. Net annual cost of therapy was based on wholesale acquisition cost. Given the model's short time horizon, disability-related costs were not included as these tend to be an important economic driver only over the long-term progression of the disease. In order to test how variability in the model's inputs might impact the analysis' results, two-way sensitivity analyses were performed based on the reported 95% risk of relapse credible intervals for SC interferon beta-1a and IM interferon beta-1a. Results: In a hypothetical cohort of 1000 RRMS patients, treatment with SC interferon beta-1a is expected to result in the avoidance of 173 (sensitivity analysis range: -20 to 399) relapses versus IM interferon beta-1a over 2 years. Assuming a direct cost of relapse of $5141, this represents a savings of $890,212 (sensitivity analysis range: -$102,138 to $2,052,934) versus IM interferon beta-1a. cOnclusiOns: Subcutaneous interferon beta-1a is likely to result in fewer relapses and lower direct costs of relapse versus IM interferon beta-1a over a 2-year period treatment.
Objectives: Gaucher disease (GD), a lysosomal storage disorder caused by mutations in the gene encoding the enzyme glucocerebrosidase, requires life-long treatment with enzyme replacement therapy (ERT). Currently available ERTs include imiglucerase, velaglucerase alfa, and taliglucerase alfa. Taliglucerase alfa is the first plant cell-expressed beta-glucocerebrosidase ERT approved for adults with type 1 GD. The purpose of this analysis was to model the potential budget impact of taliglucerase alfa therapy for GD in the United States. MethOds: A hypothetical budget impact model analysis was performed, based on total estimated number of GD patients treated, treatment costs, and estimated treatment distribution of each ERT. Costs in USD ($) per 200-unit vial were based on wholesale acquisition costs on ReadyPrice and Medi-Span databases. Annual costs were calculated using number of vials required. Actual cost savings may vary with factors beyond drug acquisition costs (eg, rebate programs) and may not reflect actual costs paid. Results: The estimated number of GD patients treated with ERT in the United States was 3,000. Drug costs for 200 units of ERT were: taliglucerase alfa-$595, velaglucerase alfa-$675, and imiglucerase-$793. Annual costs/patient were estimated at $328,440, $372,600, and $437,736 for taliglucerase alfa, velaglucerase alfa, and imiglucerase, respectively. Switching 50 patients to taliglucerase alfa, assuming same market share as national average, could save up to $4 million annually. The US health care system could save ~$100,000/patient annually if patients were switched to taliglucerase alfa. A 20% increase in the number of patients receiving taliglucerase alfa could translate to an overall savings of ~$46 million annually. cOnclusiOns: Taliglucerase alfa has the potential to provide a cost-saving alternative to other ERTs. This study was sponsored by Pfizer. Editorial support was provided by Peloton Advantage, LLC with funding from Pfizer. Campinas, Brazil, 2 Danone Specialized Nutrition, São Paulo, Brazil, 3 Nutricia,
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Objectives: Souvenaid® is a medical food -an enriched nutritional formula -that contains specific nutrients reported to be deficient in patients with Alzheimer's Disease (AD) and that are important in cognitive function, synapse formation and function. Clinical studies demonstrate that dietary management with Souvenaid® for 12 to 24 weeks results in a significant improvement in memory in patients with early AD. This study aims to estimate the budget impact of Souvenaid® for the dietary management of mild AD according to SUS perspective. MethOds: An age related incidence of AD approach was used. Population size, according to different age categories, was derived from Brazilian statistics (IBGE) and combined to estimate the number of patients per age stratum. Average cost of AD was derived from a 7-state Markov model developed to estimate the effect of Souvenaid® for mild AD versus no dietary management (NDM) of mild AD and combined with demographic data in each age stratum. Only direct costs, obtained from a public hospital in Brazil, were considered. The difference between Souvenaid® group and NDM was the 5-year budget impact estimated for SUS. Results: Considering a market penetration of 10%, 13%, 15%, 17% and 20% each year, the estimated number of patients under Souvenaid® treatment is 11.002, 15.733, 19.969, 24.894 and 32.216, respectively, for years 1-5. Compared to NDM, the inclusion of Souvenaid® in the protocol of mild Objectives: Triptan medication use is contraindicated in adults with migriane who have cardiovascular disease or cardiovascular (CV) risk factors (i.e., hypertension, diabetes, hyperlipidemia, and obesity). The objective of this study is to compare Triptan use among Migraineurs with and without cardiovascular disease (CVD) or CVD risk factors such as those with diabetes, hypertension, hyperlipidemia, and obesity. MethOds: This is a retrospective cross-sectional study using data from 2009 and 2011 Medical Expenditure Panel Survey (MEPS). The study sample consisted of adults with migraine aged 22-64 years and alive during the calendar years (N = 1,142) . Chi-square tests were used to compare rates of Triptan use among adults with and without CVD/CVD risk factors. Multiple logistic regressions were used to compare the likelihood of Triptan use among Migraineurs with and without CVD/CVD risk factors. All analyses accounted for the complex survey design of the MEPS. Results: Among adult Migraineurs, 26.3% with CVD/CVD risk and 34.3% without CVD reported Triptan medication use. After controlling for gender, age, race/ethnicity, marital status, education, employment, income level, insurance and medication coverage, perceived physical and mental health, current smoking and exercise, adults with CVD/CVD risk were less likely to use Triptans compared to adults without CVD/CVD risk. (Adjusted Odds Ratio: 0.59, 95% Confidence Interval [0.43-0.82]). cOnclusiOns: Although adults with CVD/CVD risk were less likely to report Triptan use compared to adults without CVD/CVD risk, nearly 26% of Migraineurs with CVD/CVD risk reported Triptan use. The study findings suggest that Triptan medication use among adults with CVD/CVD risk is not consistent with recommended clinical guidelines. Objectives: To estimate the budget impact of adding delayed-release dimethyl fumarate, a new oral drug indicated for the treatment of relapsing forms of multiple sclerosis (MS) to a managed care formulary in the US. MethOds: An Excel model was developed to compare the drug-related costs of the current mix of treatments with the costs of an estimated treatment mix including delayed-release dimethyl fumarate for a managed care organization (MCO) with 1,000,000 covered lives. The number of people with relapsing forms of MS was estimated using published prevalence data. Market share of delayed-release dimethyl fumarate was assumed to increase from 10% in 2013 to 25% in 2017 taken proportionately by market shares from all other DMTs. Drug costs included acquisition costs adjusted by patient payments and dispensing fees as well as administration, monitoring and adverse event costs. Annual relapse treatment costs were estimated using the relative risk reduction of a relapse for each DMT derived using a mixed-treatment comparison analysis. A one-way sensitivity analysis was performed. Results: The estimated budget impact of adding delayed-release dimethyl fumarate to the formulary was negative for the first 5 years: in 2014, with a market share of 13.0%, the estimated budget decrease was 0.29% of the total annual costs for DMT-related and relapse treatment costs and a decrease of $0.011 per member per month (PMPM); in 2017, with a market share of 25.0%, the estimated budget decrease was 0.50% of the total annual costs and a decrease of $0.018 PMPM. Sensitivity analyses showed that the model was most sensitive to the acquisition costs of delayed-release dimethyl fumarate. cOnclusiOns: Under model assumptions for market shares, adding delayed-release dimethyl fumarate to the MCO formulary would result in a small decrease in MCO costs for patients with relapsing forms of MS.
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PND11 BuDget ImPAct ANAlysIs Of usINg AmylOID POsItrON emIssION tOmOgrAPhy (Pet) IN the DIAgNOsIs Of AlzheImer's DIseAse (AD) IN the uNIteD stAtes
Hernandez L. 1 , Guo S. 1 , Sandor S. 2 1 Evidera, Lexington, MA, USA, 2 Piramal, Boston, MA, USA Objectives: In 2013, the Amyloid Imaging Taskforce (AIT) proposed that individuals with unexplained mild-cognitive impairment, possible AD, and early-onset dementia are potentially appropriate for amyloid PET in the diagnosis of AD and other forms of dementia. This analysis quantified the budgetary impact of using amyloid PET according to the AIT's criteria from the US payer perspective. MethOds: An Excel-based model was developed for this analysis. The model projects the number of patients eligible for amyloid PET over a 3-year time horizon and calculates the incremental cost of using amyloid PET by considering direct medical resource uses for diagnostic work-up, dementia medications, and dementia care for patients staying in communities or institutions. Amyloid PET's cost could be potentially offset by reducing diagnostic work-up time and resources use, unnecessary dementia treatments and delaying disease progression and time to institutional care. The model was mainly populated with data from claims data analysis (Truven MarketScan® 2007 -2012 ) and a survey of 75 dementia practitioners in the US, supplemented with data from literature, public databases, and assumptions. All costs were estimated in 2013 dollars. Results: Assuming an uptake of 5% incrementally each year, using amyloid PET increased the total cost by about $560,000 to $1,140,000 per 1 million covered lives over 3 years (or $0.016 to $0.032 per member per month) when amyloid PET's cost was set between $2,500 and $6,000 per scan. Amyloid PET's cost was partially offset by reductions in diagnostic work-up time and resources use and costs of institutional care due to more timely and accurate diagnosis and treatment. These results were most sensitive to variations in the cost of amyloid PET and time horizon. cOnclusiOns: Using amyloid PET in the diagnosis of AD
